- Home
- NUTR vs IRWD Comparison
NUTR vs IRWD Comparison
Compare NUTR & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUTR
- IRWD
- Stock Information
- Founded
- NUTR 2013
- IRWD 1998
- Country
- NUTR Indonesia
- IRWD United States
- Employees
- NUTR N/A
- IRWD N/A
- Industry
- NUTR
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- NUTR
- IRWD Health Care
- Exchange
- NUTR Nasdaq
- IRWD Nasdaq
- Market Cap
- NUTR 94.1M
- IRWD 111.2M
- IPO Year
- NUTR 2025
- IRWD 2010
- Fundamental
- Price
- NUTR $9.30
- IRWD $1.55
- Analyst Decision
- NUTR
- IRWD Buy
- Analyst Count
- NUTR 0
- IRWD 5
- Target Price
- NUTR N/A
- IRWD $4.94
- AVG Volume (30 Days)
- NUTR 2.7M
- IRWD 1.3M
- Earning Date
- NUTR 11-02-2025
- IRWD 11-06-2025
- Dividend Yield
- NUTR N/A
- IRWD N/A
- EPS Growth
- NUTR N/A
- IRWD N/A
- EPS
- NUTR 0.00
- IRWD N/A
- Revenue
- NUTR $1,743,679.00
- IRWD $308,519,000.00
- Revenue This Year
- NUTR N/A
- IRWD N/A
- Revenue Next Year
- NUTR N/A
- IRWD N/A
- P/E Ratio
- NUTR $3,995.74
- IRWD N/A
- Revenue Growth
- NUTR N/A
- IRWD N/A
- 52 Week Low
- NUTR $3.40
- IRWD $0.53
- 52 Week High
- NUTR $9.50
- IRWD $5.13
- Technical
- Relative Strength Index (RSI)
- NUTR N/A
- IRWD 62.31
- Support Level
- NUTR N/A
- IRWD $1.29
- Resistance Level
- NUTR N/A
- IRWD $1.52
- Average True Range (ATR)
- NUTR 0.00
- IRWD 0.14
- MACD
- NUTR 0.00
- IRWD 0.01
- Stochastic Oscillator
- NUTR 0.00
- IRWD 61.72
About NUTR Nusatrip Incorporated Common Stock
NusaTrip Inc operates as an Online Travel Agent offering Hotel & Flight Tickets, Domestic and International. The Company currently operates in a single reportable operating segment with five different services: Ticketing, Online advertisement, Hotel reservation, Hotel technology platform software, and Ancillary. The group earns revenue through commissions, service fees, and advertising partnerships.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.